Publication details
Co je nového v léčbě hypercholesterolemie?
| Title in English | New options in the treatment of hypercholesterolaemia |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypercholesterolemia; LDL-cholesterol; statins; ezetimibe; PCSK9-inhibitors |
| Description | Statins are the key drugs for LDL-cholesterol lowering: they have a lot of evidences that they decrease not only cholesterol, but also cardiovascular events and mortality. Second-line choice for lowering LDL-cholesterol is ezetimibe, which is intended to combination with statins. This year were published results of IMPROVE-IT study which showed that addition of ezetimibe to statin has also clinical benefit – decrease of cardiovascular events. New lipid-lowering drugs are PCSK9-inhibitors, first two of which were already approved for clinical use. |